Together with our collaborators at LMU Klinikum Munich, the German Cancer Consortium DKTK and the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) we have published a new paper in Blood, highlighting the great potential of a next-generation ADC for the effective & safe treatment of acute myeloid leukemia (AML) in preclinical in vivo models.
With a 5-year overall survival rate of 29.5% in America, AML treatment remains a challenge and the demand for new therapeutic options is high. Therefore, we utilized our novel P5 conjugation platform to create 20D9-ADC targeting a commonly occurring FTL3 mutation in AML. We could not only show a significant and durable tumor reduction but also reduced liver toxicity in preclinical cancer models. Moreover, a combined treatment with the marketed therapeutic midostaurin, a tyrosine kinase inhibitor, showed a synergistic effect broadening possible application scenarios for 20D9-ADC.
Read the full Blood article here.